The Los Angeles Post
U.S. World Business Lifestyle
Today: March 15, 2025
Today: March 15, 2025

Biohaven surges as genetic disease drug meets main study goal

Biohaven Pharmaceutical Holding Company logo is displayed on screen on floor of NYSE in New York
September 23, 2024
Reuters - Reuters

By Christy Santhosh

(Reuters) -Biohaven's drug for a genetic disease that affects the nervous system met the main study goal, sending its shares up more than 12% as the trial data allayed investor worries following a setback last year.

The company said on Monday it would submit a marketing application to the U.S. Food and Drug Administration (FDA) based on the trial and was prepared for a potential launch in 2025.

In July 2023, the health regulator declined to review the company's marketing application based on a late-stage study of the drug, troriluzole, from 2022, as it had failed to meet the main goal.

"We believe the vast majority of investors had written troriluzole off completely" said Piper Sandler analyst Christopher Raymond.

With a launch next year, Raymond sees U.S. revenue from the drug touching $250 million by 2030.

Troriluzole is part of Biohaven's non-migraine drugs spun off into a new company in 2022, after Pfizer acquired the migraine assets in an $11.6 billion deal.

In the trial, the drug showed 50% to 70% slowing of disease progression in patients with Spinocerebellar Ataxia (SCA) after three years of treatment, the company said on Monday.

SCA is caused by the degeneration of cells in brain and spinal cord and can lead to uncoordinated movement and muscle wasting.

It affects about 15,000 people in the U.S., according to company estimates, and has no approved treatments in the country.

(Reporting by Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Sriraj Kalluvila)

Related Articles

Germany's Merck in advanced talks to acquire US biotech firm SpringWorks Novo Nordisk defends next-gen obesity drug CagriSema, details new trial US FDA approves Vertex's non-opioid painkiller Surprise finding sheds light on what causes Huntington's disease, a devastating fatal brain disorder
Share This

Popular

Asia|Business|Economy|Finance

China should choose 'right timing and strength' for monetary easing, state media says

China should choose 'right timing and strength' for monetary easing, state media says
Business|Economy|Europe|Finance|Political

Greek government debt upgraded to investment grade, closing the door on a painful era

Greek government debt upgraded to investment grade, closing the door on a painful era
Arts|Business|Economy|Entertainment|Europe

West End beats Broadway in theatre revival. What's the secret?

West End beats Broadway in theatre revival. What's the secret?
Business|Technology|US

OpenAI and Musk agree to fast tracked trial over for-profit shift

OpenAI and Musk agree to fast tracked trial over for-profit shift

Health

Celebrity|Crime|Entertainment|Health|US

Gene Hackman and Betsy Arakawa's dog likely died of dehydration and starvation, report says

Gene Hackman and Betsy Arakawa's dog likely died of dehydration and starvation, report says
Health|Political|US

US FDA's top lawyer Hilary Perkins resigns two days into role

US FDA's top lawyer Hilary Perkins resigns two days into role
Americas|Health|US

Measles cases in Texas, New Mexico rise to 294 as outbreak spreads

Measles cases in Texas, New Mexico rise to 294 as outbreak spreads
Health|Science|US

FDA warns of misuse of laughing gas sold in colorful, flavored canisters

FDA warns of misuse of laughing gas sold in colorful, flavored canisters

Access this article for free.

Already have an account? Sign In